PMS2 and neoplasm: Of 204 patients with MLH1‐ and MLH1/PMS2‐deficient tumours, 199 (97·5 per cent) underwent reflex BRAF mutational testing to screen for Lynch syndrome, of whom 58 (29·1 per cent) were BRAF wild‐type.